Supplemental Material to:

Eugene K Lee, Goodwin Jinesh G, Naomi M Laing, Woonyoung Choi, David J McConkey, and Ashish M Kamat

A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin

Cancer Biology & Therapy 2012; 14(9)
http://dx.doi.org/10.4161/cbt.25326

http://www.landesbioscience.com/journals/cbt/article/25326/



Figure S1. AZ58 demonstrates variable activity as a single agent. (**A**) AZ58 demonstrated minimal single agent activity upon flow cytometry (DNA fragmentation 1–18%). (**B**) UMUC-12 was extremely sensitive (13.1% of control) and UMUC-3 was moderately sensitive (56.7% of control) to single agent Smac mimetic in a cell proliferation assay.



Figure S2. RNA expression was not predictive of cancer cell line response to drug therapy. RNA expression of XIAP, cIAP-1, Bcl-2, Bax, and Smac remained relatively constant between the cell lines. cIAP-2, Survivin, and BCLXL varied between the cell lines but did not correlate to drug sensitivity (gemcitabine and cisplatin or AZ58) or the ability of the Smac mimetic to overcome resistance to the chemotherapy.